For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 794,306 | |||
| Acquired manufacturing rights | 0 | |||
| General and administrative | 129,369 | |||
| Total operating expenses | 923,675 | |||
| Loss from operations | -923,675 | |||
| Interest income | 119,718 | |||
| Other income (expense) | 37,329 | |||
| Total other income, net | 157,047 | |||
| Net loss | -766,628 | |||
| Basic EPS | -5.63 | |||
| Diluted EPS | -5.63 | |||
| Basic Average Shares | 136,089,506 | |||
| Diluted Average Shares | 136,089,506 | |||
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)